SEC Form 4 · accession 0001394548-17-000003
SELLAS Life Sciences Group, Inc. · SLS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Bijan Nejadnik
Officer — Chief Medical Officer
Period of report
Jan 17, 2017
Accepted (ET)
Jan 19, 2017 · 7:44 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001390478
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1,F2 | $1.81 | Jan 17, 2017 | A | 30,000 | A | — | Jan 17, 2027 | Common Stock | 30,000 | 30,000 | D |
Explanation of responses
- F1Granted pursuant to the Issuer's 2016 Incentive Plan.
- F2This stock option will vest in 16 equal, quarterly installments over four years, beginning three months from the date of grant, so long as the Reporting Person remains in the company's continuous employ through the vesting period.